BiotechTube

ABBV-444 + REFRESH OPTIVE UD

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Disease

Conditions

Dry Eye Disease

Trial Timeline

Dec 15, 2025 → Nov 1, 2026

NCT ID
NCT07284381

About ABBV-444 + REFRESH OPTIVE UD

ABBV-444 + REFRESH OPTIVE UD is a phase 3 stage product being developed by AbbVie for Dry Eye Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07284381. Target conditions include Dry Eye Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07284381Phase 3Recruiting

Competing Products

20 competing products in Dry Eye Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
49
Abiprubart + PlaceboKiniksa PharmaceuticalsPhase 2
47
atomoxetine + Matching PlaceboEli LillyPhase 2
52
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
18
EvolocumabHeartFlowApproved
80
High intensity lipid loweringHeartFlowPre-clinical
18
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
72
LanifibranorInventivaPhase 2
47
LY450139 + PlaceboEli LillyPhase 3
77
Dulaglutide + PlaceboEli LillyPhase 3
77
raloxifene + placeboEli LillyPhase 3
77
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
47
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85